Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD

September 1, 2021 In Vitro Potency Assays for Assessing the Function of anti-PD-1 Checkpoint Inhibitors In this post we explore the different in vitro potency assays for assessing the function of anti-PD-1 checkpoint inhibitors, which are used to test the T cell response of anti-PD-1 (programmed death-1) agents. LEARN MORE
August 2, 2021 In vivo preclinical models for immune-mediated inflammatory disease drug development In this blog we will explore immune-mediated inflammatory diseases (IMIDs)—which represent a diverse group of ... LEARN MORE
July 5, 2021 Preclinical Models for Bispecific T Cell Engager Development Last month we hosted a webinar with Dr. Ludovic Bourré, Senior Director of Scientific Engagement at CrownBio, focused ... LEARN MORE
December 18, 2020 Factors to Consider When Selecting a Next Generation Sequencing (NGS) Technology Explore the main factors you need to consider before choosing and using next generation sequencing (NGS). LEARN MORE
October 28, 2019 Biomarker Discovery and MOA Evaluation through Genomic and Proteomic Profiling at AACR-NCI-EORTC 2019 This week in Boston we’re presenting data on our new analysis platform and preclinical technologies. This post recaps ... LEARN MORE
October 25, 2019 How to Detect, Characterize, and Evaluate CAR-Ts: Top 13 Questions Review key questions on preclinical models and rare cell analysis technology for assessing CAR-T cell therapies from ... LEARN MORE
May 7, 2019 Combination Therapies and Tumor Homograft Models Learn more about using tumor homograft models to assess oncology combination regimens, including immunotherapies. LEARN MORE
April 25, 2019 Large-Scale Immunotherapy Screening: How and Why? Learn more about the need for large-scale cancer immunotherapy screens and the different immunocompetent models ... LEARN MORE
February 6, 2019 Target Engagement Studies with Syngeneic Tumor Models Syngeneic tumor models are a rapid and high-throughput option for novel drug discovery. Here’s how to use them for ... LEARN MORE
January 29, 2019 Using Syngeneic Tumor Models for POC Studies Syngeneic tumor models are a predictive, high-throughput option for validating novel therapeutic approaches. Here’s how ... LEARN MORE